SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Bellicum Pharmaceuticals, Inc. (BLCM) .
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
Overall SharesGrow Score: 45/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — BLCM
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio1.54
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-0.81
Book Value / Share$0.00
Revenue / Share$0.05
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2013 |
$-8.11 |
$1.94M |
$-7.97M |
-410.6% |
| 2014 |
$-33.47 |
$1.78M |
$-83.97M |
-4717.1% |
| 2015 |
$-18.43 |
$282K |
$-48.55M |
-17215.6% |
| 2016 |
$-25.69 |
$388K |
$-69.24M |
-17845.6% |
| 2017 |
$-28.94 |
$185K |
$-91.78M |
-49610.3% |
| 2018 |
$-24.37 |
$1.12M |
$-98.04M |
-8753.2% |
| 2019 |
$-26.92 |
$7.14M |
$-126.09M |
-1765.3% |
| 2020 |
$-1.50 |
$500K |
$-8.62M |
-1723.8% |
| 2021 |
$-0.83 |
$6.2M |
$-9.58M |
-154.5% |
| 2022 |
$-0.81 |
$1.5M |
$-24.97M |
-1664.9% |
